New hope for rare, Fast-Spreading esophageal cancer?
NCT ID NCT07155122
Summary
This study is testing if adding an immunotherapy drug (serplulimab) to standard chemotherapy before surgery can help people with a rare and aggressive type of esophageal cancer called small cell carcinoma. The goal is to see if this combination can shrink or even eliminate the tumor before it is surgically removed, which may improve long-term outcomes. The trial will enroll about 15 patients who have not yet started treatment for their limited-stage cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL-CELL CARCINOMA OF THE ESOPHAGEAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.